Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2022-03-27 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
关于独立董事公开征集表决权公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement by an independent director collecting voting rights from shareholders for the upcoming 2021 Annual General Meeting (AGM) of the company. It details the process and conditions for shareholders to authorize the independent director to vote on their behalf on specific AGM agenda items, including equity incentive plans. The document does not contain financial statements or results, nor is it a transcript or presentation. It is an announcement related to the solicitation of votes for the AGM, specifically a Declaration of Voting Rights Announcement. The document length is under 5,000 characters and is focused on voting rights collection, not the AGM materials themselves.
2022-03-27 Chinese
中信建投证券股份有限公司关于惠州市锦好医疗科技股份有限公司2021年募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report on the 2021 fundraising funds deposit and usage situation of 惠州市锦好医疗科技股份有限公司, including amounts raised, usage, management, and compliance with regulatory requirements. It includes audit opinions from accounting firms and sponsor institution verification, detailed tables of fund usage, and explanations of any deviations or issues. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to the fundraising capital usage for the fiscal year 2021. This matches the characteristics of an Audit Report / Information (AR) as it focuses on the audit and verification of the fundraising capital usage rather than a full annual report or a simple announcement. It is not a publication announcement or a certification letter but a comprehensive audit-related report on a specific aspect of the company's financials.
2022-03-27 Chinese
2022年股权激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is titled "2022 年股权激励计划(草案)" which translates to "2022 Equity Incentive Plan (Draft)". It is issued by 惠州市锦好医疗科技股份有限公司 and details a comprehensive equity incentive plan involving stock options and restricted stock for company directors, senior management, and core employees. The document includes detailed provisions on the plan's purpose, legal basis, management structure, eligibility, allocation, pricing, vesting, and restrictions. It references relevant laws and regulatory guidelines for equity incentive plans in China, including securities laws and stock exchange rules. The document is lengthy (15,000 characters) and contains substantive content about the equity incentive plan itself, not merely an announcement or summary. It is not a financial report, earnings release, or management discussion, nor is it a proxy statement or voting result. It is a detailed plan document related to capital structure and employee compensation through equity instruments. According to the filing definitions, this type of document fits best under "Capital/Financing Update (CAP)" as it updates on company financing activities and capital structure changes through stock option and restricted stock grants. Therefore, the correct classification is CAP with high confidence.
2022-03-27 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2021' which translates to 'Annual Report 2021'. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, risk factors, corporate governance, and audited financial statements. The presence of an audit opinion from 大信会计师事务所 (DaXin CPA firm) with an unqualified opinion further confirms this is a full annual report. The document covers the full fiscal year 2021 and includes comprehensive financial and operational information, not just a summary or announcement. The length of the document (15,000 characters) and the detailed financial tables and management commentary also support classification as an Annual Report (10-K equivalent). FY 2021
2022-03-27 Chinese
监事会主席任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new chairman of the supervisory board (监事会主席任命公告) of the company. It details the election, the background of the appointee, and the impact of the appointment on the company. There is no financial data, no mention of financial results, no regulatory filings or report attachments. The content is about a change in senior management position. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and focused solely on management appointment, confirming it is not a full report or other category.
2022-03-27 Chinese
独立董事关于第二届董事会第十五次会议有关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various matters discussed at a board meeting, including the review of the 2021 annual report, financial statements, equity distribution plan, foreign exchange hedging, cash management, and a 2022 equity incentive plan. It references the 2021 annual report and financial results but does not contain the full report or detailed financial statements itself. The document is a formal opinion related to board/management matters and governance but is not the annual report or audit report itself. It is a regulatory announcement related to board meeting decisions and independent director opinions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board meeting opinions rather than full financial disclosures or presentations.
2022-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.